Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease

Brad P. Dieter, Sterling M. McPherson, Maryam Afkarian, Ian H. de Boer, Rajnish Mehrotra, Robert Short, Celestina Barbosa-Leiker, Radica Z. Alicic, Rick L. Meek, Katherine R. Tuttle

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aims To determine if serum levels of serum amyloid A (SAA) predict death and end-stage renal disease in a cohort of people with diabetic kidney disease. Methods In a longitudinal cohort study of 135 participants with type 2 diabetes and diabetic kidney disease, serum samples were assayed for SAA. Censored time-to-event analyses in Cox-proportional hazard models were utilized to assess SAA as a predictor of the primary outcome of death and end-stage renal disease. Results Participants were 73% Mexican-American (99/135) and 55% men (75/135), with a mean ± SD age of 57 ± 7.5 years. At baseline, participants had hemoglobin A1c of 8.6 ± 2.3%, systolic blood pressure of 153 ± 27 mm Hg, body mass index of 31 ± 9 kg/m2, median urine-albumin-to-creatinine ratio of 1861 mg/g (interquartile range 720–3912 mg/g), and estimated glomerular filtration rate of 55.7 ± 22.3 ml/min/1.73 m2. Over a median duration of follow-up of 3.5 years, 44% (60/135) of participants experienced a primary outcome event. The hazards ratio for the primary outcome was 3.03 (95% CI 1.43–6.40, p = 0.003) in the highest (> 1.0 μg/ml) compared to the lowest (< 0.55 μg/ml) SAA tertile in a model adjusted for urine-albumin-to-creatinine ratio, estimated glomerular filtration rate, age, sex, and race/ethnicity. Addition of SAA as a covariate improved the model C-statistic (Δ c = 0.017). Conclusions In a longitudinal cohort study of participants with type 2 diabetes and DKD, higher levels of serum SAA predicted higher risk of death and ESRD. SAA is a promising targetable biomarker for DKD.

Original languageEnglish (US)
Pages (from-to)1467-1472
Number of pages6
JournalJournal of Diabetes and its Complications
Volume30
Issue number8
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

Serum Amyloid A Protein
Diabetic Nephropathies
Amyloid
Chronic Kidney Failure
Serum
Glomerular Filtration Rate
Type 2 Diabetes Mellitus
Longitudinal Studies
Albumins
Creatinine
Cohort Studies
Urine
Blood Pressure
Proportional Hazards Models
Hemoglobins
Body Mass Index
Biomarkers

Keywords

  • Biomarkers
  • Chronic kidney disease
  • Diabetes
  • Inflammation
  • Risk-stratification

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease. / Dieter, Brad P.; McPherson, Sterling M.; Afkarian, Maryam; de Boer, Ian H.; Mehrotra, Rajnish; Short, Robert; Barbosa-Leiker, Celestina; Alicic, Radica Z.; Meek, Rick L.; Tuttle, Katherine R.

In: Journal of Diabetes and its Complications, Vol. 30, No. 8, 01.11.2016, p. 1467-1472.

Research output: Contribution to journalArticle

Dieter, BP, McPherson, SM, Afkarian, M, de Boer, IH, Mehrotra, R, Short, R, Barbosa-Leiker, C, Alicic, RZ, Meek, RL & Tuttle, KR 2016, 'Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease', Journal of Diabetes and its Complications, vol. 30, no. 8, pp. 1467-1472. https://doi.org/10.1016/j.jdiacomp.2016.07.018
Dieter, Brad P. ; McPherson, Sterling M. ; Afkarian, Maryam ; de Boer, Ian H. ; Mehrotra, Rajnish ; Short, Robert ; Barbosa-Leiker, Celestina ; Alicic, Radica Z. ; Meek, Rick L. ; Tuttle, Katherine R. / Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease. In: Journal of Diabetes and its Complications. 2016 ; Vol. 30, No. 8. pp. 1467-1472.
@article{f073e2379761462192f086d0bfc31255,
title = "Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease",
abstract = "Aims To determine if serum levels of serum amyloid A (SAA) predict death and end-stage renal disease in a cohort of people with diabetic kidney disease. Methods In a longitudinal cohort study of 135 participants with type 2 diabetes and diabetic kidney disease, serum samples were assayed for SAA. Censored time-to-event analyses in Cox-proportional hazard models were utilized to assess SAA as a predictor of the primary outcome of death and end-stage renal disease. Results Participants were 73{\%} Mexican-American (99/135) and 55{\%} men (75/135), with a mean ± SD age of 57 ± 7.5 years. At baseline, participants had hemoglobin A1c of 8.6 ± 2.3{\%}, systolic blood pressure of 153 ± 27 mm Hg, body mass index of 31 ± 9 kg/m2, median urine-albumin-to-creatinine ratio of 1861 mg/g (interquartile range 720–3912 mg/g), and estimated glomerular filtration rate of 55.7 ± 22.3 ml/min/1.73 m2. Over a median duration of follow-up of 3.5 years, 44{\%} (60/135) of participants experienced a primary outcome event. The hazards ratio for the primary outcome was 3.03 (95{\%} CI 1.43–6.40, p = 0.003) in the highest (> 1.0 μg/ml) compared to the lowest (< 0.55 μg/ml) SAA tertile in a model adjusted for urine-albumin-to-creatinine ratio, estimated glomerular filtration rate, age, sex, and race/ethnicity. Addition of SAA as a covariate improved the model C-statistic (Δ c = 0.017). Conclusions In a longitudinal cohort study of participants with type 2 diabetes and DKD, higher levels of serum SAA predicted higher risk of death and ESRD. SAA is a promising targetable biomarker for DKD.",
keywords = "Biomarkers, Chronic kidney disease, Diabetes, Inflammation, Risk-stratification",
author = "Dieter, {Brad P.} and McPherson, {Sterling M.} and Maryam Afkarian and {de Boer}, {Ian H.} and Rajnish Mehrotra and Robert Short and Celestina Barbosa-Leiker and Alicic, {Radica Z.} and Meek, {Rick L.} and Tuttle, {Katherine R.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.jdiacomp.2016.07.018",
language = "English (US)",
volume = "30",
pages = "1467--1472",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease

AU - Dieter, Brad P.

AU - McPherson, Sterling M.

AU - Afkarian, Maryam

AU - de Boer, Ian H.

AU - Mehrotra, Rajnish

AU - Short, Robert

AU - Barbosa-Leiker, Celestina

AU - Alicic, Radica Z.

AU - Meek, Rick L.

AU - Tuttle, Katherine R.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Aims To determine if serum levels of serum amyloid A (SAA) predict death and end-stage renal disease in a cohort of people with diabetic kidney disease. Methods In a longitudinal cohort study of 135 participants with type 2 diabetes and diabetic kidney disease, serum samples were assayed for SAA. Censored time-to-event analyses in Cox-proportional hazard models were utilized to assess SAA as a predictor of the primary outcome of death and end-stage renal disease. Results Participants were 73% Mexican-American (99/135) and 55% men (75/135), with a mean ± SD age of 57 ± 7.5 years. At baseline, participants had hemoglobin A1c of 8.6 ± 2.3%, systolic blood pressure of 153 ± 27 mm Hg, body mass index of 31 ± 9 kg/m2, median urine-albumin-to-creatinine ratio of 1861 mg/g (interquartile range 720–3912 mg/g), and estimated glomerular filtration rate of 55.7 ± 22.3 ml/min/1.73 m2. Over a median duration of follow-up of 3.5 years, 44% (60/135) of participants experienced a primary outcome event. The hazards ratio for the primary outcome was 3.03 (95% CI 1.43–6.40, p = 0.003) in the highest (> 1.0 μg/ml) compared to the lowest (< 0.55 μg/ml) SAA tertile in a model adjusted for urine-albumin-to-creatinine ratio, estimated glomerular filtration rate, age, sex, and race/ethnicity. Addition of SAA as a covariate improved the model C-statistic (Δ c = 0.017). Conclusions In a longitudinal cohort study of participants with type 2 diabetes and DKD, higher levels of serum SAA predicted higher risk of death and ESRD. SAA is a promising targetable biomarker for DKD.

AB - Aims To determine if serum levels of serum amyloid A (SAA) predict death and end-stage renal disease in a cohort of people with diabetic kidney disease. Methods In a longitudinal cohort study of 135 participants with type 2 diabetes and diabetic kidney disease, serum samples were assayed for SAA. Censored time-to-event analyses in Cox-proportional hazard models were utilized to assess SAA as a predictor of the primary outcome of death and end-stage renal disease. Results Participants were 73% Mexican-American (99/135) and 55% men (75/135), with a mean ± SD age of 57 ± 7.5 years. At baseline, participants had hemoglobin A1c of 8.6 ± 2.3%, systolic blood pressure of 153 ± 27 mm Hg, body mass index of 31 ± 9 kg/m2, median urine-albumin-to-creatinine ratio of 1861 mg/g (interquartile range 720–3912 mg/g), and estimated glomerular filtration rate of 55.7 ± 22.3 ml/min/1.73 m2. Over a median duration of follow-up of 3.5 years, 44% (60/135) of participants experienced a primary outcome event. The hazards ratio for the primary outcome was 3.03 (95% CI 1.43–6.40, p = 0.003) in the highest (> 1.0 μg/ml) compared to the lowest (< 0.55 μg/ml) SAA tertile in a model adjusted for urine-albumin-to-creatinine ratio, estimated glomerular filtration rate, age, sex, and race/ethnicity. Addition of SAA as a covariate improved the model C-statistic (Δ c = 0.017). Conclusions In a longitudinal cohort study of participants with type 2 diabetes and DKD, higher levels of serum SAA predicted higher risk of death and ESRD. SAA is a promising targetable biomarker for DKD.

KW - Biomarkers

KW - Chronic kidney disease

KW - Diabetes

KW - Inflammation

KW - Risk-stratification

UR - http://www.scopus.com/inward/record.url?scp=84981717392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981717392&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2016.07.018

DO - 10.1016/j.jdiacomp.2016.07.018

M3 - Article

C2 - 27522272

AN - SCOPUS:84981717392

VL - 30

SP - 1467

EP - 1472

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 8

ER -